Company Profile
Pharvaris Stock Price, News & Analysis
- Ticker:
- PHVS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Netherlands
Stock performance
33.65 USD (-0.96%)
Close
Last updated: July 28, 2026
2.03B USD
Market cap
Why the stock is moving
As of Jul 28, 2026, PHVS closed down 0.96% at $33.65. No new same-company headline was identified in the current news window.
Company overview
Business overview
Pharvaris is a hereditary-angioedema company focused on oral therapies for severe rare disease. Its goal is to create a more convenient option in a high-value orphan market.
Geographic Base and Sector Classification
Headquartered in the Netherlands and listed on NASDAQ as an ADR, Pharvaris has a global rare-disease profile.
Business Model Characteristics
The model depends on clinical data, oral differentiation, and the ability to build an HAE franchise.
Position Within the Biotechnology Landscape
Pharvaris is a focused rare-disease name whose stock can move on proof of efficacy and convenience.
Future catalysts
Pharvaris’s next catalysts are deucrictibant and the hereditary-angioedema program. The market will care about dose, efficacy, and whether the oral bradykinin story still looks strong.
Recent news
- 01
- 02
- 03
- 04
Pharvaris Announces Annual General Meeting of Shareholders
Source: Pharvaris
- 05
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
Source: Pharvaris
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Pharvaris (PHVS)?
Pharvaris (PHVS) most recently closed at 33.65 USD, a -0.96% move versus the previous session.
What is the market cap of Pharvaris (PHVS)?
Pharvaris currently has a market capitalization of 2.03B USD on BioPharmSignal.
What does Pharvaris do?
Pharvaris is a hereditary-angioedema company focused on oral therapies for severe rare disease. Its goal is to create a more convenient option in a high-value orphan market.
On which exchange is PHVS stock listed?
Pharvaris (PHVS) is associated with NASDAQ, Netherlands, Biopharma.
What is Pharvaris?
Pharvaris’s next catalysts are deucrictibant and the hereditary-angioedema program.
Which conditions is Pharvaris targeting with Pharvaris?
Pharvaris is associated with rare disease based on its company overview and current catalyst commentary.
How does Pharvaris describe recent progress with Pharvaris?
Pharvaris’s next catalysts are deucrictibant and the hereditary-angioedema program.
What future catalysts are investors watching for Pharvaris?
Pharvaris’s next catalysts are deucrictibant and the hereditary-angioedema program. The market will care about dose, efficacy, and whether the oral bradykinin story still looks strong.